Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 73

1.

The selective estrogen receptor modulator arzoxifene and the rexinoid LG100268 cooperate to promote transforming growth factor beta-dependent apoptosis in breast cancer.

Rendi MH, Suh N, Lamph WW, Krajewski S, Reed JC, Heyman RA, Berchuck A, Liby K, Risingsong R, Royce DB, Williams CR, Sporn MB.

Cancer Res. 2004 May 15;64(10):3566-71.

PMID:
15150113
[PubMed - indexed for MEDLINE]
Free Article
2.

The combination of the rexinoid, LG100268, and a selective estrogen receptor modulator, either arzoxifene or acolbifene, synergizes in the prevention and treatment of mammary tumors in an estrogen receptor-negative model of breast cancer.

Liby K, Rendi M, Suh N, Royce DB, Risingsong R, Williams CR, Lamph W, Labrie F, Krajewski S, Xu X, Kim H, Brown P, Sporn MB.

Clin Cancer Res. 2006 Oct 1;12(19):5902-9.

PMID:
17020999
[PubMed - indexed for MEDLINE]
Free Article
3.

Comparison of the selective estrogen receptor modulator arzoxifene (LY353381) with tamoxifen on tumor growth and biomarker expression in an MCF-7 human breast cancer xenograft model.

Detre S, Riddler S, Salter J, A'Hern R, Dowsett M, Johnston SR.

Cancer Res. 2003 Oct 1;63(19):6516-22.

PMID:
14559845
[PubMed - indexed for MEDLINE]
Free Article
4.

Prevention and treatment of experimental breast cancer with the combination of a new selective estrogen receptor modulator, arzoxifene, and a new rexinoid, LG 100268.

Suh N, Lamph WW, Glasebrook AL, Grese TA, Palkowitz AD, Williams CR, Risingsong R, Farris MR, Heyman RA, Sporn MB.

Clin Cancer Res. 2002 Oct;8(10):3270-5.

PMID:
12374698
[PubMed - indexed for MEDLINE]
Free Article
5.
6.

Arzoxifene, a new selective estrogen receptor modulator for chemoprevention of experimental breast cancer.

Suh N, Glasebrook AL, Palkowitz AD, Bryant HU, Burris LL, Starling JJ, Pearce HL, Williams C, Peer C, Wang Y, Sporn MB.

Cancer Res. 2001 Dec 1;61(23):8412-5.

PMID:
11731420
[PubMed - indexed for MEDLINE]
Free Article
7.

Agents with selective estrogen receptor (ER) modulator activity induce apoptosis in vitro and in vivo in ER-negative glioma cells.

Hui AM, Zhang W, Chen W, Xi D, Purow B, Friedman GC, Fine HA.

Cancer Res. 2004 Dec 15;64(24):9115-23.

PMID:
15604281
[PubMed - indexed for MEDLINE]
Free Article
8.

Nuclear factor-kappaB activation: a molecular therapeutic target for estrogen receptor-negative and epidermal growth factor receptor family receptor-positive human breast cancer.

Singh S, Shi Q, Bailey ST, Palczewski MJ, Pardee AB, Iglehart JD, Biswas DK.

Mol Cancer Ther. 2007 Jul;6(7):1973-82.

PMID:
17620428
[PubMed - indexed for MEDLINE]
Free Article
9.

Prevention and treatment of experimental estrogen receptor-negative mammary carcinogenesis by the synthetic triterpenoid CDDO-methyl Ester and the rexinoid LG100268.

Liby K, Risingsong R, Royce DB, Williams CR, Yore MM, Honda T, Gribble GW, Lamph WW, Vannini N, Sogno I, Albini A, Sporn MB.

Clin Cancer Res. 2008 Jul 15;14(14):4556-63. doi: 10.1158/1078-0432.CCR-08-0040.

PMID:
18628471
[PubMed - indexed for MEDLINE]
Free Article
10.

Structure-activity relationships for a family of benzothiophene selective estrogen receptor modulators including raloxifene and arzoxifene.

Overk CR, Peng KW, Asghodom RT, Kastrati I, Lantvit DD, Qin Z, Frasor J, Bolton JL, Thatcher GR.

ChemMedChem. 2007 Oct;2(10):1520-6.

PMID:
17654759
[PubMed - indexed for MEDLINE]
11.

The combination of tamoxifen and the rexinoid LG100268 prevents ER-positive and ER-negative mammary tumors in p53-null mammary gland mice.

Mazumdar A, Medina D, Kittrell FS, Zhang Y, Hill JL, Edwards DE, Bissonnette RP, Brown PH.

Cancer Prev Res (Phila). 2012 Oct;5(10):1195-202. doi: 10.1158/1940-6207.CAPR-11-0524. Epub 2012 Aug 27.

PMID:
22926341
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Neu-induced retroviral rat mammary carcinogenesis: a novel chemoprevention model for both hormonally responsive and nonresponsive mammary carcinomas.

Woditschka S, Haag JD, Waller JL, Monson DM, Hitt AA, Brose HL, Hu R, Zheng Y, Watson PA, Kim K, Lindstrom MJ, Mau B, Steele VE, Lubet RA, Gould MN.

Cancer Res. 2006 Jul 1;66(13):6884-91.

PMID:
16818667
[PubMed - indexed for MEDLINE]
Free Article
13.

Breast cancer chemoprevention phase I evaluation of biomarker modulation by arzoxifene, a third generation selective estrogen receptor modulator.

Fabian CJ, Kimler BF, Anderson J, Tawfik OW, Mayo MS, Burak WE Jr, O'Shaughnessy JA, Albain KS, Hyams DM, Budd GT, Ganz PA, Sauter ER, Beenken SW, Grizzle WE, Fruehauf JP, Arneson DW, Bacus JW, Lagios MD, Johnson KA, Browne D.

Clin Cancer Res. 2004 Aug 15;10(16):5403-17.

PMID:
15328178
[PubMed - indexed for MEDLINE]
Free Article
14.

Inactivation of NF-kappaB by 3,3'-diindolylmethane contributes to increased apoptosis induced by chemotherapeutic agent in breast cancer cells.

Rahman KM, Ali S, Aboukameel A, Sarkar SH, Wang Z, Philip PA, Sakr WA, Raz A.

Mol Cancer Ther. 2007 Oct;6(10):2757-65. Epub 2007 Oct 3.

PMID:
17913854
[PubMed - indexed for MEDLINE]
Free Article
15.

The Rexinoid LG100268 prevents the development of preinvasive and invasive estrogen receptor negative tumors in MMTV-erbB2 mice.

Li Y, Zhang Y, Hill J, Shen Q, Kim HT, Xu X, Hilsenbeck SG, Bissonnette RP, Lamph WW, Brown PH.

Clin Cancer Res. 2007 Oct 15;13(20):6224-31.

PMID:
17947490
[PubMed - indexed for MEDLINE]
Free Article
16.

Prevention of breast cancer: current state of the science and future opportunities.

Uray IP, Brown PH.

Expert Opin Investig Drugs. 2006 Dec;15(12):1583-600. Review.

PMID:
17107283
[PubMed - indexed for MEDLINE]
17.

Randomized, double-blind, multicenter trial comparing two doses of arzoxifene (LY353381) in hormone-sensitive advanced or metastatic breast cancer patients.

Baselga J, Llombart-Cussac A, Bellet M, Guillem-Porta V, Enas N, Krejcy K, Carrasco E, Kayitalire L, Kuta M, Lluch A, Vodvarka P, Kerbrat P, Namer M, Petruzelka L.

Ann Oncol. 2003 Sep;14(9):1383-90.

PMID:
12954577
[PubMed - indexed for MEDLINE]
Free Article
18.

LAS, a novel selective estrogen receptor modulator with chemopreventive and therapeutic activity in the N-nitroso-N-methylurea-induced rat mammary tumor model.

Cohen LA, Pittman B, Wang CX, Aliaga C, Yu L, Moyer JD.

Cancer Res. 2001 Dec 15;61(24):8683-8.

PMID:
11751385
[PubMed - indexed for MEDLINE]
Free Article
19.

Curcumin suppresses the paclitaxel-induced nuclear factor-kappaB pathway in breast cancer cells and inhibits lung metastasis of human breast cancer in nude mice.

Aggarwal BB, Shishodia S, Takada Y, Banerjee S, Newman RA, Bueso-Ramos CE, Price JE.

Clin Cancer Res. 2005 Oct 15;11(20):7490-8.

PMID:
16243823
[PubMed - indexed for MEDLINE]
Free Article
20.

Induction of apoptosis in estrogen receptor-negative breast cancer cells by natural and synthetic cyclopentenones: role of the IkappaB kinase/nuclear factor-kappaB pathway.

Ciucci A, Gianferretti P, Piva R, Guyot T, Snape TJ, Roberts SM, Santoro MG.

Mol Pharmacol. 2006 Nov;70(5):1812-21. Epub 2006 Aug 14.

PMID:
16908599
[PubMed - indexed for MEDLINE]
Free Article
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk